In another session on science policy, MethylGene’s Chief Medical Officer, Dr. Rachel Humphrey, will give a presentation on the use of biomarkers in clinical development.
Poster Presentation
The Combination of MGCD265, a Met/VEGFR Inhibitor in Clinical Development, and Erlotinib Potently Inhibits Tumor Growth by Altering Multiple Pathways Including Glycolysis
Date and Time: Monday Apr 2, 2012 8:00 AM - 12:00 PM (CT)
Session: Experimental and Molecular Therapeutics 11
Abstract No.: 1790
Location: Hall F, Poster Section 29
Science Policy Session
Dr. Humphrey’s presentation is entitled “Biomarkers in clinical development: Strategic considerations”.
Date and Time: Monday Apr 2, 2012 1:30 - 1:50 PM (CT)
Session: SP03. Scientific and Regulatory Challenges in Codevelopment of Predictive In Vitro Diagnostics
Location: McCormick Place South (Level 1), Room S103
About MGCD265
MGCD265 is a novel, oral small molecule inhibitor that targets a unique spectrum of receptor tyrosine kinases: Met, VEGFR 1, 2, and 3, Tie-2 and Ron. These kinases play key roles in tumor development, survival and metastasis as well as the inappropriate formation of blood vessels (angiogenesis) that nourish the tumor. MGCD265 has completed one Phase 1 single agent study, and is nearing completion of one Phase 1 single agent clinical trial and one Phase 1/2 combination clinical trial (with erlotinib and docetaxel) in solid tumors.
About MethylGene
MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is currently in Phase 2 trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.
Investor Relations Contact:
Joseph Walewicz, CFA
Vice President, Business & Corporate Development
MethylGene Inc.
Phone: 514-337-3333 ext. 373
ir@methylgene.com
www.methylgene.com
Thomas Fechtner
Vice President
The Trout Group LLC
Phone: 646-378-2931
tfechtner@troutgroup.com
www.troutgroup.com
